Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses first-line treatment options for advanced colorectal cancer (CRC).
- First-line treatment options for patients with advanced CRC are influenced byRASmutation status
- Patients with wild-typeRASare treated with chemotherapy plus anti-EGFR agents, such as panitumumab or cetuximab
- Data from the PRIME trial, which compared FOLFOX plus panitumumab to panitumumab alone, showed that patients treated with panitumumab plus FOLFOX had an improvement in overall survival
- The retrospective study of the CRYSTAL study and data from the FIRE study show that cetuximab prolongs overall survival longer than 30 months in patients who haveRASwild-type disease.